EUCTR2015-002549-72-PL进行中（未招募）1 期
A Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage IIIB and IIIC melanoma patients. - Neoadjuvant L19IL2/L19TNF- Pivotal study
Philogen S.p.A.0 个研究点目标入组 214 人开始时间: 2017年1月17日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 214
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of malignant melanoma of the skin with locally advanced disease as defined by clinical stage III B and III C according to AJCC 7th Ed, eligible for complete surgical resection.
- •2. Eligible subjects must have measurable disease and must be candidate for intralesional therapy with at least one injectable cutaneous, subcutaneous, or nodal melanoma lesion (= 10 mm in longest diameter) or with multiple injectable lesions that in aggregate have a longest diameter of = 10 mm.
- •3. Prior anti-tumor treatment for the primary melanoma lesion, including surgery and approved adjuvant treatments (e.g., radiotherapy, immune checkpoint inhibitors, BRAF/MEK inhibitors, etc.) is allowed.
- •4. Males or females, age = 18 years
- •5. ECOG Performance Status/WHO Performance Status = 1
- •6. Life expectancy of at least 24 months (see paragraph 6.3.1)
- •7. Absolute neutrophil count > 1.5 x 109/L
- •8. Hemoglobin > 9.0 g/dL
- •9. Platelets > 100 x 109/L
- •10. Total bilirubin = 30 µmol/L (or = 2.0 mg/dl)
- •11. ALT and AST = 2.5 x the upper limit of normal (ULN)
- •12. Serum creatinine < 1.5 x ULN
- •13. LDH serum level = 1.5 x ULN
- •14. Documented negative test for HIV, HBV and HCV. For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV (e.g. anti-HBsAg and/or anti-HBc Ab) negative serum HBV-DNA is also required.
- •15. All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v4.03) Grade = 1 unless otherwise specified above
- •16. Negative pregnancy test at screening for Women Of Childbearing Potential (WOCBP*). Pregnant women are not allowed to participate to this study. WOCBP must be using, from the screening to three months following the last study drug administration, highly effective contraception methods, as defined by the Recommendations for contraception and pregnancy testing in clinical trials issued by the Head
- •of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with
- •inhibition of ovulation, intrauterine devices, intrauterine hormonereleasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence. Pregnancy test will be repeated at the Safety Visit
- •(only WOCBP and only for patients in Arm 1).
- •17. Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e., spermicidal gel plus condom) from the screening to three months following the last study drug administration.
- •18. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
- •19. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
- •*Women of childbearing potential are defined as females who have experienced menarche, are not postmenopausal (12 months with no menses without an alternative medical cause) and are not permanently
- •sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of su
排除标准
- •Patients exclusion criteria:
- •1. Uveal melanoma, mucosal melanoma or melanoma with unknown primary.
- •2. Evidence of distant metastases at screening
- •3. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1), second primary melanoma in situ or any cancer curatively treated = 5 years prior to study entry
- •4. Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the
- •5. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
- •6. Inadequately controlled cardiac arrhythmias including atrial fibrillation
- •7. Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria)
- •8. LVEF = 50% and/or abnormalities observed during baseline ECG and Echocardiogram investigations that are considered as clinically significant by the investigator.
- •9. Uncontrolled hypertension
- •10. Ischemic peripheral vascular disease (Grade IIb-IV)
- •11. Severe diabetic retinopathy
- •12. Active autoimmune disease
- •13. History of organ allograft or stem cell transplantation
- •14. Recovery from major trauma including surgery within 4 weeks prior to enrollment.
- •15. Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies or any other constituent of the product.
- •16. Breast feeding female
- •17. Anti-tumor therapy (except allowed treatments listed at point 3 of Inclusion criteria) within 4 weeks before enrollment
- •18. Previous in vivo exposure to monoclonal antibodies for biological therapy (except allowed treatments listed at point 3 of Inclusion criteria) in the 6 weeks before enrollment
- •19. Planned administration of growth factors or immunomodulatory agents (except allowed treatments listed at point 3 of Inclusion criteria) within 7 days before enrollment
- •20. Patient requiring or taking corticosteroids or other immunosuppressant drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.
- •21. Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.
- •22. Previous enrolment and randomization in this same study.
研究者
相似试验
进行中（未招募）
1 期
Study of the efficacy of intratumoral injections of L19IL2/L19TNF followed by surgery to prevent or retard appearance of new metastasesMalignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions.MedDRA version: 21.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002549-72-DEPhilogen S.p.A.214
进行中（未招募）
1 期
Study of the efficacy of intratumoral injections of L19IL2/L19TNF followed by surgery to prevent or retard appearance of new metastasesMalignant melanoma of the skin in subjects with completely resectable stage IIIB and IIIC disease and presence of injectable cutaneous and/or subcutaneous or nodal lesions.MedDRA version: 20.0Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002549-72-FRPhilogen S.p.A.214
进行中（未招募）
3 期
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior 1st / 2nd Generation EGFR-TKI or Osimertinib Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)Carcinoma, Non-Small-Cell LungJPRN-jRCT2041210072Suzuki Kazuyuki245
进行中（未招募）
1 期
Study of safety and efficacy of capmatinib in combination with osimertinib compared to platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR activating mutations and T790M negative who have progressed on prior EGFR-TKI therapyEGFR mutated, T790M negative NSCLCMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003677-21-BGovartis Pharma AG6
进行中（未招募）
1 期
Study of safety and efficacy of capmatinib in combination with osimertinib compared to platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR activating mutations and T790M negative who have progressed on prior EGFR-TKI therapyEUCTR2020-003677-21-HUovartis Pharma AG245